Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

APAC is intended for in-hospital use and can be administered either locally or by IV infusion. Johanna Asklin, General Partner at FSG, stated: “Thrombo-inflammation is a key underlying driver for many ...

Cancer treatment decisions are complex, requiring consideration of both medical advancements and individual patient needs, including emotional and physical conditions. There is often a gap between the ...

The most common treatment-emergent adverse events were paronychia, infusion-related reactions, and rash. “Today’s approval marks an important moment in lung cancer care,” said Henar Hevia, Ph.D., ...